Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Bicycle Therapeutics plc made materially false and/or misleading statements and/or failed to disclose that: On October 31, 2025, RBC Capital Markets analyst Leonid Timashev downgraded Bicycle to Sector Perform from Outperform, citing delays in development of zelenectide pevedotin, which is in phase 2/3 development for metastatic urothelial cancer, due to pushing dose selection to the first quarter of 2026. Timashev noted that the urothelial cancer treatment space is growing more competitive, and asserted that any further delays from Bicycle will only help sales of a competing Pfizer product. Following this news, Bicycle's American Depositary Receipt ("ADR") price fell over 7% on the same day.
In order to be eligible to join the BCYC class action lawsuit, you must have incurred a loss on shares of Bicycle Therapeutics plc purchased during the class period listed above.
TOP
